Bayer spotlights positive PhIII data for fat-busting drug

Bayer Healthcare touted upbeat data from a pair of late-stage studies of an investigational drug targeting chin fat, setting the stage for the giant to step into growing aesthetic treatment market. And the results provide a victory from Kythera ($KYTH), which licensed the injected drug to Bayer for markets outside the U.S. and Canada. Kythera and Bayer's ATX-101, a synthetic version of a human...